M&As this week: Yestar International, Sividon Diagnostics, Myriad Genetics

2 June 2016 (Last Updated June 2nd, 2016 18:30)

Sichuan Maker Biotechnology, an in-vitro diagnostic reagents producer, plans to acquire 24.2% stake in Jiashan JASDAQ Medical Device Co Ltd for CNY15m ($2.27m). The acquisition will increase Sichuan's share in the company to 57.2%.

Sichuan Maker Biotechnology, an in-vitro diagnostic reagents producer, plans to acquire 24.2% stake in Jiashan JASDAQ Medical Device Co Ltd for CNY15m ($2.27m). The acquisition will increase Sichuan's share in the company to 57.2%.

Breast cancer prognostic company, Sividon Diagnostics GmbH has been acquired by Myriad Genetics, a molecular diagnostic company based in the US.

Myriad Genetics has agreed to pay up to €50m ($55.61m), of which €35m ($38.93m) will be paid as an upfront payment and the remaining will be paid at performance-based milestones.

"Myriad Genetics has agreed to pay up to €50m ($55.61m), of which €35m ($38.93m) will be paid as an upfront payment and the remaining will be paid at performance-based milestones."

The transaction, which was closed on 31 May 2016, allows Myriad Genetics to add Sividon Diagnostics' EndoPredict test, a popular breast cancer prognostic test, to its global oncology distribution thus enabling it to strengthen its oncology portfolio of high-value, personalised medicine products.

Yestar International Holdings Company plans to acquire a China-based medical device company from an independent third party